131 related articles for article (PubMed ID: 32977662)
1. Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate.
Taussky D; Soulieres D; Chagnon M; Delouya G; Bahig H
Cells; 2020 Sep; 9(10):. PubMed ID: 32977662
[TBL] [Abstract][Full Text] [Related]
2. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
3. The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.
Krishnan V; Delouya G; Bahary JP; Larrivée S; Taussky D
BJU Int; 2014 Dec; 114(6):865-71. PubMed ID: 24274784
[TBL] [Abstract][Full Text] [Related]
4. Role of Neutrophil to Lymphocyte Ratio or Platelet to Lymphocyte Ratio in Prediction of Bone Metastasis of Prostate Cancer.
Zhang JY; Ge P; Zhang PY; Zhao M; Ren L
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115239
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil count is associated with survival in localized prostate cancer.
Bahig H; Taussky D; Delouya G; Nadiri A; Gagnon-Jacques A; Bodson-Clermont P; Soulieres D
BMC Cancer; 2015 Aug; 15():594. PubMed ID: 26292807
[TBL] [Abstract][Full Text] [Related]
6. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
7. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
8. High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy.
Lee H; Jeong SJ; Hong SK; Byun SS; Lee SE; Oh JJ
World J Urol; 2016 Jun; 34(6):821-7. PubMed ID: 26449784
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.
Kwon YS; Han CS; Yu JW; Kim S; Modi P; Davis R; Park JH; Lee P; Ha YS; Kim WJ; Kim IY
Clin Genitourin Cancer; 2016 Feb; 14(1):e1-8. PubMed ID: 26341038
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the Cancer of the Prostate Risk Assessment to predict for biochemical failure after external beam radiotherapy or prostate seed brachytherapy.
Delouya G; Krishnan V; Bahary JP; Larrivée S; Taussky D
Urology; 2014 Sep; 84(3):629-33. PubMed ID: 25168545
[TBL] [Abstract][Full Text] [Related]
11. Comparison of AUA and phoenix definitions of biochemical failure following permanent brachytherapy for prostate cancer.
Gul ZG; Say R; Skouteris VM; Stock RG; Stone NN
Brachytherapy; 2022; 21(6):833-838. PubMed ID: 35902336
[TBL] [Abstract][Full Text] [Related]
12. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy.
Tetreault-Laflamme A; Crook J; Hamm J; Pickles T; Keyes M; McKenzie M; Pai H; Bachand F; Morris J
J Urol; 2018 Jan; 199(1):120-125. PubMed ID: 28827105
[TBL] [Abstract][Full Text] [Related]
14. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.
Morris WJ; Pickles T; Keyes M
Brachytherapy; 2018; 17(6):837-844. PubMed ID: 30245169
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone.
Nakai Y; Tanaka N; Asakawa I; Anai S; Miyake M; Morizawa Y; Hori S; Owari T; Fujii T; Yamaki K; Hasegawa M; Fujimoto K
Jpn J Clin Oncol; 2020 Jan; 50(1):58-65. PubMed ID: 31665354
[TBL] [Abstract][Full Text] [Related]
16. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer.
Cuaron J; Pei X; Cohen GN; Cox BW; Yamada Y; Zelefsky MJ; Kollmeier MA
Brachytherapy; 2015; 14(2):179-84. PubMed ID: 25500364
[TBL] [Abstract][Full Text] [Related]
17. Assessment of permanent brachytherapy combined with androgen deprivation therapy in an intermediate-risk prostate cancer group without a Gleason score of 4 + 3: a single Japanese institutional experience.
Okihara K; Kobayashi K; Iwata T; Naitoh Y; Kamoi K; Kawauchi A; Yamada K; Miki T
Int J Urol; 2014 Mar; 21(3):271-6. PubMed ID: 24033545
[TBL] [Abstract][Full Text] [Related]
18. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.
Routman DM; Funk RK; Stish BJ; Mynderse LA; Wilson TM; McLaren R; Harmsen WS; Mara K; Deufel CL; Furutani KM; Haddock MG; Pisansky TM; Choo CR; Davis BJ
Brachytherapy; 2019; 18(1):1-7. PubMed ID: 30293836
[TBL] [Abstract][Full Text] [Related]
19. High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.
Pickles T; Morris WJ; Keyes M
Brachytherapy; 2017; 16(6):1101-1105. PubMed ID: 29032014
[TBL] [Abstract][Full Text] [Related]
20. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
